Free cash flow remains deeply negative, with quarterly outflows reaching as high as $29.8 million in 2025Q3, necessitating reliance on external financing to sustain operations.
| Cash from Operations | -97.99M | -98.56M | -81.15M | -59.5M | -54.56M | -44.18M | -3.13M |
| Operating CF Margin % | - | - | - | - | -8342.51% | -2666.39% | -604.35% |
| Operating CF Growth % | -69.26% | -21.45% | -36.4% | -9.05% | -23.49% | -1310.04% | - |
| Net Income | -87.5M | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M | -5.15M |
| Depreciation & Amortization | 1.99M | 379K | 2M | 1.84M | 1.15M | 13K | 0 |
| Stock-Based Compensation | 11.19M | 12.13M | 12.47M | 3.04M | 1.78M | 386K | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -3.22M | -1.6M | -23K | 530K | 0 | 0 | 1.87M |
| Working Capital Changes | -20.45M | -9.52M | 2.73M | 1.48M | 1.79M | 6.04M | 150.15K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -8.3M | -1.56M | 2.38M | -180K | -426K | 3.02M | 44.32K |
| Cash from Investing | -78.39M | -90.25M | -94.08M | -165K | -901K | -188K | 0 |
| Capital Expenditures | -432K | -397K | -481K | -115K | -672K | -188K | 0 |
| CapEx % of Revenue | - | - | - | - | 102.75% | 11.35% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 17K | 17K | 0 | -50K | -229K | 0 | 0 |
| Cash from Financing | 219.24M | 216.79M | 88.78M | 103.79M | 189K | 150.86M | 32.38M |
| Debt Issued (Net) | -495K | -533K | -410K | 3.58M | -163K | 0 | 2.6M |
| Equity Issued (Net) | 226.61M | 217.33M | 88.69M | 100.25M | 20K | 151.06M | 30M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -17K | 0 | 0 | 0 | 0 |
| Other Financing | -6.88M | 0 | 491K | -35K | 332K | -203K | -223.59K |
| Net Change in Cash | 42.85M | 27.98M | -86.45M | 44.13M | -55.27M | 106.49M | 29.25M |
| Free Cash Flow | -98.42M | -98.96M | -81.63M | -59.66M | -55.46M | -44.37M | -3.13M |
| FCF Margin % | - | - | - | - | -8480.28% | -2677.73% | -604.35% |
| FCF Growth % | -11.48% | -21.22% | -36.83% | -7.57% | -25% | -1316.04% | - |
| FCF per Share | -1.21 | -1.84 | -2.57 | -2.24 | -2.20 | -1.76 | -0.12 |
| FCF Conversion (FCF/Net Income) | 1.12x | 0.99x | 0.83x | 0.90x | 0.92x | 0.87x | 0.61x |
| Interest Paid | 0 | 0 | 127K | 176K | 77K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and dilution
According to the provided cash flow statements, LXEO's operating cash flow consistently tracks net losses, with the OCF/NI ratio fluctuating between 0.60 and 1.46, indicating that non-cash adjustments like stock-based compensation are insufficient to bridge the gap between accounting losses and actual cash outflows.
The tight correlation between net income and operating cash flow confirms that the company's burn is driven by core operational activities rather than accounting anomalies. Investors should note that the variability in this ratio suggests lumpy R&D spending patterns that may complicate short-term liquidity forecasting.
As reported in financial statements, LXEO's free cash flow remains deeply negative, with quarterly outflows ranging from $14.1 million to $29.8 million, underscoring the company's total dependence on external capital to sustain its clinical-stage research and development pipeline without any offsetting commercial revenue streams.
The absence of positive free cash flow is expected for a pre-revenue biotech, yet the magnitude of these outflows relative to the $63 million cash balance warrants close scrutiny. This trajectory implies that the company is effectively consuming its remaining liquidity at a rate that necessitates a capital market event in the near term.
Based on the reported figures, working capital changes have been highly erratic, swinging from a $7.4 million inflow in 2024Q3 to a $12.5 million outflow in 2025Q3, which suggests significant variability in the timing of vendor payments and clinical trial milestone obligations.
These fluctuations indicate that the company's cash position is sensitive to the timing of contract research organization payments and other operational liabilities. Such volatility makes it difficult to project the exact date of cash exhaustion, as working capital management appears to be reactive rather than strategic.
Data from recent filings reveals that stock-based compensation, which averaged approximately $2.8 million per quarter, serves as a critical non-cash expense that artificially narrows the reported net loss while failing to mitigate the underlying cash burn required to support the company's scientific workforce.
While SBC is a standard tool for talent retention in biotechnology, it obscures the true cost of operations by shifting the burden of compensation from cash to equity dilution. Analysts should interpret the cash flow statement with the understanding that the company's operational viability is currently subsidized by the willingness of employees to accept equity in lieu of cash.
Quick answers to the most common questions about buying LXEO stock.
Lexeo Therapeutics, Inc. Common Stock (LXEO) generated $-98.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Lexeo Therapeutics, Inc. Common Stock (LXEO) reported negative free cash flow of $99.0M in 2025, indicating capital requirements exceeded cash from operations.
Lexeo Therapeutics, Inc. Common Stock (LXEO) spent $0.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.